Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

This study is currently recruiting participants.
Verified June 2012 by University of California, San Francisco
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00483249
First received: June 5, 2007
Last updated: June 28, 2012
Last verified: June 2012
  Purpose

This is a study to assess the safety and effectiveness of endovascular treatment of thoracoabdominal (TAAA) and paravisceral abdominal (PVAAA) aortic aneurysms. The investigational operation involves placing a stent-graft over the aortic aneurysm.


Condition Intervention Phase
Thoracoabdominal Aortic Aneurysm
Paravisceral Abdominal Aortic Aneurysm
Device: Endovascular Branched Stent-Graft
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Successful implantation of TAAA branched stent-graft. [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Long term success of TAAA branched stent-graft treatment. [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 120
Study Start Date: May 2005
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Endovascular Branched Stent-Graft
    Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
Detailed Description:

A TAAA or PVAAA is an abnormal enlargement of the aorta, the main artery in the chest and abdomen. The standard operation for TAAA of PVAAA is performed through a long incision extending down the side of the chest and the front of the abdomen. In the standard operation, the weak area of the aorta is replaced with a fabric sleeve (graft). The investigational operation is done making small incisions in both groins and the right arm and placing a graft in the aorta through tubes that are inserted through the femoral and brachial arteries, than fastening it in position with metal springs(stents). The combination of a stent and a graft is known as a stent-graft. Compared with standard operation, the potential advantages of endovascular TAAA/PVAAA repair include less pain, less disturbance of intestinal function, a lower risk of pulmonary or cardiac complications and shorter hospital stay. The main disadvantage of endovascular TAAA/PVAAA is an unknown success rate.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aneurysm >6cm in diameter or >5cm in diameter which is enlarging at a rate of >10mm/year
  • Anticipated mortality > 20% with conventional surgical treatment
  • Life expectancy > 2 years
  • Absence of a dominant artery to the spinal cord arising from the are of stent-graft implantation
  • Ability to give informed consent and willingness to comply with follow-up schedule
  • Suitable arterial anatomy for endovascular repair

Exclusion Criteria:

  • Free rupture of the aneurysm
  • Pregnancy
  • Anaphylactic reaction to contrast material
  • Allergy to stainless steel or polyester
  • Unwillingness or inability to comply with the follow up schedule
  • Serious systemic or groin infection
  • Uncorrectable coagulopathy
  • Inability to give informed consent in English
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00483249

Contacts
Contact: Linda M Reilly, MD 415 353 4366 linda.reilly@ucsfmedctr.org
Contact: Timothy AM Chuter, MD 415 353 4366 timothy.chuter@ucsfmedctr.org

Locations
United States, California
Division of Vascular Surgery, UCSF Recruiting
San Francisco, California, United States, 94143
Principal Investigator: Timothy AM Chuter, MD            
Principal Investigator: Linda M Reilly, MD            
Sub-Investigator: Jade S Hiramoto, MD            
Division of Vascular Surgery, SFVAMC Recruiting
San Francisco, California, United States, 94121
Principal Investigator: Joseph H Rapp, MD            
Principal Investigator: Timothy AM Chuter, MD            
Principal Investigator: Linda M Reilly, MD            
Sub-Investigator: Marlene Grenon, MD            
Sponsors and Collaborators
University of California, San Francisco
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00483249     History of Changes
Other Study ID Numbers: H5357-26067
Study First Received: June 5, 2007
Last Updated: June 28, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:
Thoracoabdominal
Paravisceral
Aneurysm
Endovascular
Stent-Graft

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Aortic Aneurysm, Thoracic
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases

ClinicalTrials.gov processed this record on May 19, 2013